KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Equity Average (2016 - 2025)

Acadia Pharmaceuticals has reported Equity Average over the past 15 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Equity Average at $1.1 billion for Q4 2025, up 63.72% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (up 63.72% YoY), and the annual figure for FY2025 was $980.1 million, up 68.32%.
  • Equity Average for Q4 2025 was $1.1 billion at Acadia Pharmaceuticals, up from $869.8 million in the prior quarter.
  • Over the last five years, Equity Average for ACAD hit a ceiling of $1.1 billion in Q4 2025 and a floor of $379.0 million in Q3 2023.
  • Median Equity Average over the past 5 years was $519.9 million (2022), compared with a mean of $562.3 million.
  • Biggest five-year swings in Equity Average: fell 25.43% in 2022 and later skyrocketed 67.23% in 2025.
  • Acadia Pharmaceuticals' Equity Average stood at $553.9 million in 2021, then fell by 25.43% to $413.0 million in 2022, then fell by 3.89% to $397.0 million in 2023, then soared by 65.0% to $655.0 million in 2024, then soared by 63.72% to $1.1 billion in 2025.
  • The last three reported values for Equity Average were $1.1 billion (Q4 2025), $869.8 million (Q3 2025), and $793.8 million (Q2 2025) per Business Quant data.